GlycoNex Partners with Nippon Kayaku to Develop Tumor-Activated ADC GNX201 for Solid Tumors
核心洞察
GlycoNex Inc. (搜索) and Nippon Kayaku Co., Ltd. have entered a collaboration to advance GNX201-ADC (搜索), a next-generation antibody-drug conjugate designed for solid tumor treatment.
The ADC candidate features protease-activated technology that remains stable in circulation and selectively activates in the tumor microenvironment to minimize toxicity.
GNX201-ADC (搜索) leverages GlycoNex's "Antibody Lock" technology, incorporating a pro-ADC design that targets tumor-associated glycan (搜索) antigens while sparing healthy tissue.
GlycoNex Inc. (搜索), a clinical-stage biotechnology company focused on glycan-directed cancer (搜索) immunotherapies, announced a collaboration agreement with Nippon Kayaku Co., Ltd. to advance GNX201-ADC (搜索), a next-generation antibody-drug conjugate candidate for solid tumor treatment. The partnership will jointly support preclinical development activities, leveraging both companies' expertise in antibody engineering and oncology drug development.
Novel Protease-Activated ADC Design
GNX201-ADC (搜索) is designed as a protease-activated ADC that remains stable in circulation and is selectively activated in the tumor microenvironment, enabling targeted delivery of its cytotoxic payload while minimizing effects on normal tissues. This differentiated pro-antibody activation strategy is intended to improve therapeutic index and reduce on-target toxicity compared with conventional ADC approaches.
The ADC candidate leverages GlycoNex's "Antibody Lock" technology, incorporating a protease-activated pro-ADC that is "turned on" when the masking peptide is removed in the tumor microenvironment and turned off with the masked domain when in circulation. This selective activation allows GNX201-ADC (搜索) to target tumors without harming healthy tissue, aiming to reduce the risk of on-target toxicity and associated adverse effects observed with conventional ADC approaches.
Collaboration Focus and Development Strategy
The collaboration will center on research and development activities for GNX201-ADC (搜索) including optimization of the ADC construct and generation of preclinical data to support regulatory submissions. Initial development efforts will focus on solid tumors (搜索) characterized by high levels of glycan antigens (搜索).
"GlycoNex has long been dedicated to advancing anti-glycan antibodies and tumor glycobiology, and ADCs represent a natural extension of that scientific focus," said Dr. Mei-Chun Yang, CEO of GlycoNex. "We are honored to collaborate with Nippon Kayaku to combine our complementary R&D strengths, clinical development capabilities, and regulatory expertise to accelerate GNX201-ADC (搜索) and advance the program toward clinical studies."
Strategic Partnership Benefits
For GlycoNex, this collaboration further strengthens the company's growing ADC pipeline and reflects its broader strategy of leveraging glycan-directed antibody technologies to develop novel precision oncology therapies. The company's robust pipeline is led by GNX102, a humanized monoclonal antibody designed to target abnormal sugar molecules in cancer (搜索) cells, which has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy.
"We are pleased to partner with GlycoNex on GNX201-ADC (搜索), a program that brings a differentiated pro-antibody activation concept into an ADC modality," said Akira Masuda, General Manager of Pharmaceutical Research Laboratories of Nippon Kayaku. "By combining GlycoNex's expertise in tumor-associated glycan (搜索) targeting with Nippon Kayaku's experience in oncology-related pharmaceuticals, we aim to advance preclinical development and generate the data needed to support future clinical evaluation and treatment options for patients."
For Nippon Kayaku, the partnership expands its oncology research portfolio through access to a differentiated targeting modality with potential application across multiple solid tumor indications. The century-old chemical and pharmaceutical manufacturer operates through three business domains, including Life Science, which delivers oncology-related pharmaceutical products.